♥

Venus Remedies Limited

ISIN : INE411B01019
NSE : VENUSREM
BSE : 526953
Face Value : 10
Industry : Pharmaceuticals & Drugs

EPS : 21.31
EPS (TTM) : 16.54
Price to Earning (P/E) : 14.05
Book Value : 364.74
Price to Bookvalue (P/B) : 0.82
Dividend Yield : 0 %
Return on Equity (ROE) : 6.01 %
Return on Capital Employed (ROCE) : 8.67 %

Venus Remedies share price (02-Apr-2026)
National Stock Exchange NSE
Open / Close	0 - 0 NAN %
Low / High	0 - 0 NAN %
Trade Volume	0
52 Week Low / High	0 - 0 NAN %
Bombay Stock Exchange BSE
Open / Close	860 - 897.4 4.3 %
Low / High	844 - 908.35 7.6 %
Trade Volume	16,603
52 Week Low / High	295 - 950 222 %

YOU MAY ALSO LIKE

High dividend stocks
High dividend yield stocks on Stock exchange NSE and BSE
Low PE ratio stocks
Undervalued, low PE ratio stocks on Stock exchange NSE and BSE
CAGR Calculator
Check your investment returns using our CAGR / Investment Growth Calculator
How much money do you need to retire
Know how much money do you need to retire, before how much to invest ?
Stock market course tutorial
Stock Market Investment Course explained in simple words.
Share Market basics for beginners
Share Market jargons in simple terms

Consolidated Standalone

CONSOLIDATED QUARTERLY RESULT FOR VENUS REMEDIES LIMITED

Date End	Jun 2022	Sep 2022	Dec 2022	Mar 2023	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024
No of months	3 months	3 months	3 months	3 months	3 months	3 months	3 months	3 months	3 months	3 months
Net Sales	1430.8	1398.9	1169	1556.4	951.5	1677.2	1434.2	1951.6	1086.1	1674.5
Total Income	1445.2	1416.8	1207.1	1590.5	974.1	1707.7	1457.7	1990.8	1102	1780.3
Total Expenditure	1285.7	1269.2	1088	1310.3	847.5	1499.3	1313.8	1756.8	973.5	1625.4
Other Income	14.4	17.9	38.1	34.1	22.6	30.5	23.5	39.2	15.9	105.8
Operating Profit	159.5	147.6	119.1	280.2	126.6	208.4	143.9	234	128.5	154.9
Interest	2.6		1.5		0.6	0.6	0.7	0.2	0.2	0.2
PBDT	156.9	147.6	117.6	280.2	126	207.8	143.2	233.8	128.3	154.7
Depreciation	78	89.9	72.2	82.9	75.5	64.4	65.4	59.1	59.8	64
Profit Before Tax	78.9	57.7	45.4	197.3	50.5	143.4	77.8	174.7	68.5	90.7
Tax	10	4.4	12.5	86.7	38.7	44	9.3	69.6	56.3	55.6
Profit After Tax	68.9	53.3	32.9	110.6	11.8	99.4	68.5	105.1	12.2	35.1
Net Profit	68.9	53.3	32.9	110.6	11.8	99.4	68.5	105.1	12.2	35.1
Equity Capital	133.7	133.7	133.7	133.7	133.7	133.7	133.7	133.7	133.7	133.7
Face Value (IN RS)	10	10	10	10	10	10	10	10	10	10
Calculated EPS	5.15	3.99	2.46	8.27	0.88	7.43	5.12	7.86	0.91	2.63
Diluted Eps After Extraordinary Items	5.16	3.99	2.46	8.27	0.88	7.44	5.13	7.86	0.92	2.63
Diluted Eps Before Extraordinary Items	5.16	3.99	2.46	8.27	0.88	7.44	5.13	7.86	0.92	2.63

STANDALONE QUARTERLY RESULT FOR VENUS REMEDIES LIMITED

Date End	Jun 2022	Sep 2022	Dec 2022	Mar 2023	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024
No of months	3 months	3 months	3 months	3 months	3 months	3 months	3 months	3 months	3 months	3 months
Net Sales	1549.3	1247.5	1094.5	1485.3	986.3	1701.9	1312.3	1751.6	1058.6	1670.2
Total Income	1563.4	1265.2	1132	1517.7	1006.9	1731.2	1336.5	1790.7	1074.2	1777.3
Total Expenditure	1366.8	1095.8	1023.7	1275	851.6	1570.6	1182.3	1538.8	915.8	1567.5
Other Income	14.1	17.7	37.5	32.4	20.6	29.3	24.2	39.1	15.6	107.1
Operating Profit	196.6	169.4	108.3	242.7	155.3	160.6	154.2	251.9	158.4	209.8
PBDT	196.6	169.4	108.3	242.7	155.3	160.6	154.2	251.9	158.4	209.8
Depreciation	75.7	87.7	69.7	80.6	73.2	62.1	63	57.2	57.6	61.7
Profit Before Tax	120.9	81.7	38.6	162.1	82.1	98.5	91.2	194.7	100.8	148.1
Tax	10	4.4	12.5	86.7	38.7	44	9.3	69.6	56.3	55.5
Profit After Tax	110.9	77.3	26.1	75.4	43.4	54.5	81.9	125.1	44.5	92.6
Net Profit	110.9	77.3	26.1	75.4	43.4	54.5	81.9	125.1	44.5	92.6
Equity Capital	133.7	133.7	133.7	133.7	133.7	133.7	133.7	133.7	133.7	133.7
Face Value (IN RS)	10	10	10	10	10	10	10	10	10	10
Calculated EPS	8.29	5.78	1.95	5.64	3.25	4.08	6.13	9.36	3.33	6.93
Diluted Eps After Extraordinary Items	8.3	5.78	1.95	5.64	3.25	4.07	6.13	9.36	3.33	6.92
Diluted Eps Before Extraordinary Items	8.3	5.78	1.95	5.64	3.25	4.07	6.13	9.36	3.33	6.92

Consolidated Standalone

CONSOLIDATED ANNUAL RESULT FOR VENUS REMEDIES LIMITED

Date End	Mar 2022	Mar 2023	Mar 2024
No of months	12 months	12 months	12 months
Net Sales	5986.5	5555.1	6014.5
Total Income	6069.59	5658.3	6130.3
Total Expenditure	5365.36	4953.1	5418.6
Other Income	83.09	103.2	115.8
Operating Profit	704.23	705.2	711.7
Interest	4.81	2.9	0.9
PBDT	699.42	702.3	710.8
Depreciation	335.34	323	264.4
Profit Before Tax	364.08	379.3	446.4
Tax	-43.16	113.6	161.5
Profit After Tax	407.24	265.7	284.9
Net Profit	407.24	265.7	284.9
Equity Capital	133.67	133.7	133.7
Face Value (IN RS)	10	10	10
Reserves	4270.79	4469.7	4741.8
Calculated EPS	30.47	19.87	21.31
Diluted Eps After Extraordinary Items	30.86	19.88	21.31
Diluted Eps Before Extraordinary Items	30.86	19.88	21.31

STANDALONE ANNUAL RESULT FOR VENUS REMEDIES LIMITED

Date End	Mar 2022	Mar 2023	Mar 2024
No of months	12 months	12 months	12 months
Net Sales	5751.81	5376.6	5752.1
Total Income	5836.1	5478.3	5865.3
Total Expenditure	5063.6	4761.3	5143.3
Other Income	84.29	101.7	113.2
Operating Profit	772.5	717	722
PBDT	772.5	717	722
Depreciation	325.8	313.7	255.5
Profit Before Tax	446.7	403.3	466.5
Tax	-43.16	113.7	161.5
Profit After Tax	489.86	289.6	305
Net Profit	489.86	289.6	305
Equity Capital	133.67	133.7	133.7
Face Value (IN RS)	10	10	10
Reserves	4360.46	4646.8	4952.2
Calculated EPS	36.65	21.66	22.81
Diluted Eps After Extraordinary Items	37.12	21.67	22.82
Diluted Eps Before Extraordinary Items	37.12	21.67	22.82

Consolidated Standalone

CONSOLIDATED PROFIT / LOSS FOR VENUS REMEDIES LIMITED

YEAR	Mar 2021	Mar 2022	Mar 2023	Mar 2024
No of Months	12 months	12 months	12 months	12 months
Gross Sales	548.12 Cr	598.65 Cr	555.51 Cr	601.45 Cr
Sales	537.68 Cr	597.98 Cr	552.44 Cr	591.21 Cr
Net Sales	548.12 Cr	598.65 Cr	555.51 Cr	601.45 Cr
Increase/Decrease in Stock	-7.15 Cr	3.48 Cr	8.04 Cr	-2.66 Cr
Raw Material Consumed	347.94 Cr	381.97 Cr	322.95 Cr	357.35 Cr
Opening Raw Materials	86.42 Cr	66.04 Cr	75.4 Cr	77.63 Cr
Purchases Raw Materials	327.56 Cr	391.33 Cr	320.02 Cr	341.68 Cr
Closing Raw Materials	66.04 Cr	75.4 Cr	77.63 Cr	75.03 Cr
Other Direct Purchases / Brought in cost	0	0	5.16 Cr	13.07 Cr
Power & Fuel Cost	4.58 Cr	4.71 Cr	5.52 Cr	6.35 Cr
Electricity & Power	4.58 Cr	4.71 Cr	5.52 Cr	6.35 Cr
Employee Cost	46.02 Cr	52.33 Cr	57.05 Cr	66.95 Cr
Salaries, Wages & Bonus	40.49 Cr	45.9 Cr	49.74 Cr	58.43 Cr
Contributions to EPF & Pension Funds	3.75 Cr	3.67 Cr	3.92 Cr	4.21 Cr
Workmen and Staff Welfare Expenses	1.77 Cr	2.76 Cr	3.39 Cr	4.31 Cr
Other Manufacturing Expenses	22.86 Cr	31.57 Cr	32.4 Cr	28.77 Cr
Repairs and Maintenance	1.8 Cr	2.4 Cr	2.19 Cr	1.88 Cr
General and Administration Expenses	16.45 Cr	16.91 Cr	20.7 Cr	23.7 Cr
Rent , Rates & Taxes	53.41 Lk	82.86 Lk	86.47 Lk	1.33 Cr
Insurance	51.97 Lk	63.62 Lk	77.09 Lk	74.79 Lk
Printing and stationery	21.56 Lk	30.98 Lk	37.66 Lk	45.64 Lk
Professional and legal fees	1.18 Cr	84.44 Lk	99.23 Lk	1.13 Cr
Traveling and conveyance	3.34 Cr	4.72 Cr	6.22 Cr	7.58 Cr
Selling and Distribution Expenses	63.64 Cr	45.56 Cr	48.4 Cr	61.09 Cr
Advertisement & Sales Promotion	2.9 Cr	4.43 Cr	8.48 Cr	13.25 Cr
Sales Commissions & Incentives	3.14 Cr	3.68 Cr	4.2 Cr	2.17 Cr
Miscellaneous Expenses	0	0	25.84 Lk	31.03 Lk
Total Expenditure	494.35 Cr	536.54 Cr	495.31 Cr	541.85 Cr
Other Income	19.63 Cr	8.31 Cr	10.32 Cr	11.58 Cr
Interest Received	12.22 Lk	81.6 Lk	1.9 Cr	4.17 Cr
Foreign Exchange Gains	6.49 Cr	6.42 Cr	7.32 Cr	5.95 Cr
Operating Profit	73.41 Cr	70.42 Cr	70.52 Cr	71.18 Cr
Interest	13.02 Cr	48.1 Lk	29.44 Lk	9.37 Lk
Bank Charges etc	6.01 Cr	17.8 Lk	14.22 Lk	0
PBDT	60.39 Cr	69.94 Cr	70.23 Cr	71.09 Cr
Depreciation	35.28 Cr	33.53 Cr	32.3 Cr	26.44 Cr
Profit Before Taxation & Exceptional Items	25.11 Cr	36.41 Cr	37.93 Cr	44.64 Cr
Exceptional Income / Expenses	23.44 Cr	0	0	0
Profit Before Tax	48.55 Cr	36.41 Cr	37.93 Cr	44.64 Cr
Provision for Tax	-13.21 Cr	-4.32 Cr	11.36 Cr	16.15 Cr
Current Income Tax	0	0	0	11.74 Cr
Deferred Tax	-13.21 Cr	-4.32 Cr	11.36 Cr	3.93 Cr
Profit After Tax	61.77 Cr	40.72 Cr	26.57 Cr	28.49 Cr
Consolidated Net Profit	61.77 Cr	40.72 Cr	26.57 Cr	28.49 Cr
Profit Balance B/F	13.39 Cr	75.06 Cr	116.02 Cr	142.13 Cr
Appropriations	75.15 Cr	115.78 Cr	142.59 Cr	170.62 Cr
Other Appropriation	9.52 Lk	-24.39 Lk	46.27 Lk	18.74 Lk
Earnings Per Share	50.04	30.47	19.87	21.31
Adjusted EPS	50.04	30.47	19.87	21.31

STANDALONE PROFIT / LOSS FOR VENUS REMEDIES LIMITED

YEAR	Mar 2021	Mar 2022	Mar 2023	Mar 2024
No of Months	12 months	12 months	12 months	12 months
Gross Sales	514.62 Cr	575.18 Cr	537.66 Cr	575.21 Cr
Sales	504.17 Cr	574.52 Cr	535.1 Cr	564.42 Cr
Net Sales	514.62 Cr	575.18 Cr	537.66 Cr	575.21 Cr
Increase/Decrease in Stock	-7.36 Cr	3.19 Cr	14.26 Cr	-5 Cr
Raw Material Consumed	344.04 Cr	372.78 Cr	322.44 Cr	357.22 Cr
Opening Raw Materials	86.42 Cr	66.04 Cr	75.4 Cr	77.63 Cr
Purchases Raw Materials	323.66 Cr	382.14 Cr	319.51 Cr	341.55 Cr
Closing Raw Materials	66.04 Cr	75.4 Cr	77.63 Cr	75.03 Cr
Other Direct Purchases / Brought in cost	0	0	5.16 Cr	13.07 Cr
Power & Fuel Cost	3.39 Cr	3.78 Cr	4.17 Cr	4.99 Cr
Electricity & Power	3.39 Cr	3.78 Cr	4.17 Cr	4.99 Cr
Employee Cost	35.89 Cr	43.75 Cr	47.67 Cr	57.57 Cr
Salaries, Wages & Bonus	32.14 Cr	38.82 Cr	42.06 Cr	50.82 Cr
Contributions to EPF & Pension Funds	2.02 Cr	2.2 Cr	2.14 Cr	2.48 Cr
Workmen and Staff Welfare Expenses	1.73 Cr	2.72 Cr	3.48 Cr	4.28 Cr
Other Manufacturing Expenses	20.63 Cr	25.48 Cr	25.46 Cr	22.4 Cr
Repairs and Maintenance	1.65 Cr	2.24 Cr	1.91 Cr	1.63 Cr
General and Administration Expenses	13.76 Cr	15.01 Cr	18.63 Cr	21.23 Cr
Rent , Rates & Taxes	38.91 Lk	62.44 Lk	46.09 Lk	65.9 Lk
Insurance	36.92 Lk	45.75 Lk	55 Lk	56.21 Lk
Printing and stationery	18.97 Lk	27.44 Lk	34.27 Lk	40 Lk
Professional and legal fees	25.34 Lk	6.47 Lk	12.73 Lk	20.84 Lk
Traveling and conveyance	3.33 Cr	4.66 Cr	6.31 Cr	7.61 Cr
Selling and Distribution Expenses	57.4 Cr	42.37 Cr	43.24 Cr	55.62 Cr
Advertisement & Sales Promotion	2.92 Cr	4.42 Cr	8.35 Cr	12.06 Cr
Sales Commissions & Incentives	3.14 Cr	3.68 Cr	4.2 Cr	2.17 Cr
Miscellaneous Expenses	0	0	25.84 Lk	31.01 Lk
Total Expenditure	467.76 Cr	506.36 Cr	476.14 Cr	514.32 Cr
Other Income	17.76 Cr	8.43 Cr	10.17 Cr	11.32 Cr
Interest Received	12.21 Lk	76.64 Lk	1.9 Cr	4.16 Cr
Foreign Exchange Gains	6.04 Cr	6.73 Cr	7.32 Cr	5.8 Cr
Operating Profit	64.62 Cr	77.25 Cr	71.7 Cr	72.21 Cr
Interest	12.73 Cr	0	0	0
Bank Charges etc	5.92 Cr	0	0	0
PBDT	51.9 Cr	77.25 Cr	71.7 Cr	72.21 Cr
Depreciation	34.28 Cr	32.58 Cr	31.37 Cr	25.55 Cr
Profit Before Taxation & Exceptional Items	17.62 Cr	44.67 Cr	40.33 Cr	46.65 Cr
Exceptional Income / Expenses	23.44 Cr	0	0	0
Profit Before Tax	41.06 Cr	44.67 Cr	40.33 Cr	46.65 Cr
Provision for Tax	-13.21 Cr	-4.32 Cr	11.36 Cr	16.15 Cr
Current Income Tax	0	0	0	11.74 Cr
Deferred Tax	-13.21 Cr	-4.32 Cr	11.36 Cr	3.93 Cr
Profit After Tax	54.27 Cr	48.99 Cr	28.96 Cr	30.5 Cr
Consolidated Net Profit	54.27 Cr	48.99 Cr	28.96 Cr	30.5 Cr
Adjustments to PAT	0	-3,000	0	0
Profit Balance B/F	32.85 Cr	87.02 Cr	136.26 Cr	164.76 Cr
Appropriations	87.12 Cr	136.01 Cr	165.22 Cr	195.26 Cr
Other Appropriation	9.52 Lk	-24.39 Lk	46.27 Lk	18.74 Lk
Earnings Per Share	43.97	36.65	21.67	22.82
Adjusted EPS	43.97	36.65	21.67	22.82

Consolidated Standalone

CONSOLIDATED CASH FLOW FOR VENUS REMEDIES LIMITED

Year End	Mar 2021	Mar 2022	Mar 2023	Mar 2024
No of Months	12 months	12 months	12 months	12 months
Profit Before Tax	25.11 Cr	36.41 Cr	37.93 Cr	44.64 Cr
Adjustment	23.4 Cr	26.33 Cr	23.33 Cr	20.23 Cr
Changes In working Capital	60.67 Cr	-21.74 Cr	-24.63 Cr	-12.11 Cr
Cash Flow after changes in Working Capital	109.17 Cr	41 Cr	36.63 Cr	52.77 Cr
Cash Flow from Operating Activities	132.61 Cr	41 Cr	36.63 Cr	37.29 Cr
Cash Flow from Investing Activities	55.72 Cr	-16.63 Cr	-50.83 Cr	-7.21 Cr
Cash Flow from Financing Activitie	-162.24 Cr	-9.48 Cr	-56.75 Lk	-1.08 Cr
Net Cash Inflow / Outflow	26.09 Cr	14.9 Cr	-14.77 Cr	28.99 Cr
Opening Cash & Cash Equivalents	1.94 Cr	28.88 Cr	43.26 Cr	21.21 Cr
Effect of Foreign Exchange Fluctuations	84.88 Lk	-52.14 Lk	-7.27 Cr	-1.25 Cr
Closing Cash & Cash Equivalent	28.88 Cr	43.26 Cr	21.21 Cr	48.96 Cr

STANDALONE CASH FLOW FOR VENUS REMEDIES LIMITED

Year End	Mar 2021	Mar 2022	Mar 2023	Mar 2024
No of Months	12 months	12 months	12 months	12 months
Profit Before Tax	17.62 Cr	44.67 Cr	40.33 Cr	46.65 Cr
Adjustment	22.64 Cr	24.83 Cr	22.25 Cr	19.36 Cr
Changes In working Capital	68.96 Cr	-28.6 Cr	-34.53 Cr	-15.15 Cr
Cash Flow after changes in Working Capital	109.22 Cr	40.9 Cr	28.05 Cr	50.87 Cr
Cash Flow from Operating Activities	132.67 Cr	40.9 Cr	28.05 Cr	35.38 Cr
Cash Flow from Investing Activities	55.65 Cr	-16.65 Cr	-50.81 Cr	-6.94 Cr
Cash Flow from Financing Activitie	-161.88 Cr	-9.13 Cr	0	0
Net Cash Inflow / Outflow	26.44 Cr	15.12 Cr	-22.76 Cr	28.44 Cr
Opening Cash & Cash Equivalents	1.26 Cr	27.7 Cr	42.83 Cr	20.07 Cr
Closing Cash & Cash Equivalent	27.7 Cr	42.83 Cr	20.07 Cr	48.51 Cr

Consolidated Standalone

CONSOLIDATED BALANCE SHEET FOR VENUS REMEDIES LIMITED

YEAR	Mar 2021	Mar 2022	Mar 2023	Mar 2024
Share Capital	12.34 Cr	13.37 Cr	13.37 Cr	13.37 Cr
Equity - Authorised	20 Cr	20 Cr	20 Cr	20 Cr
Equity - Issued	12.34 Cr	13.37 Cr	13.37 Cr	13.37 Cr
Equity Paid Up	12.34 Cr	13.37 Cr	13.37 Cr	13.37 Cr
Face Value	10	10	10	10
Total Reserves	374.19 Cr	427.08 Cr	446.97 Cr	474.18 Cr
Securities Premium	75.6 Cr	88.33 Cr	88.33 Cr	88.33 Cr
Profit & Loss Account Balance	75.06 Cr	116.02 Cr	142.13 Cr	170.43 Cr
General Reserves	211.46 Cr	211.46 Cr	211.46 Cr	211.46 Cr
Reserve excluding Revaluation Reserve	374.19 Cr	427.08 Cr	446.97 Cr	474.18 Cr
Shareholder's Funds	400.28 Cr	440.45 Cr	460.34 Cr	487.55 Cr
Secured Loans	9.39 Lk	0	0	0
Term Loans - Banks	9.39 Lk	0	0	0
Unsecured Loans	46.74 Cr	38.68 Cr	38.68 Cr	38.68 Cr
Foreign Currency Convertible Notes	38.68 Cr	38.68 Cr	38.68 Cr	38.68 Cr
Loans - Others	8.06 Cr	0	0	0
Deferred Tax Assets / Liabilities	3.63 Cr	-68.21 Lk	10.65 Cr	10.92 Cr
Deferred Tax Assets	33.85 Cr	26.99 Cr	10.34 Cr	6.82 Cr
Deferred Tax Liability	37.49 Cr	26.31 Cr	20.99 Cr	17.74 Cr
Other Long Term Liabilities	28.35 Lk	0	0	0
Long Term Provisions	7.38 Cr	7.95 Cr	8.85 Cr	10.26 Cr
Total Non-Current Liabilities	58.12 Cr	45.95 Cr	58.17 Cr	59.86 Cr
Trade Payables	71.36 Cr	54.29 Cr	50.84 Cr	44.14 Cr
Sundry Creditors	71.36 Cr	54.29 Cr	50.84 Cr	44.14 Cr
Other Current Liabilities	21.1 Cr	33.64 Cr	27.23 Cr	31.57 Cr
Advances received from customers	3.19 Cr	11.96 Cr	5.52 Cr	4.76 Cr
Short Term Borrowings	4.3 Cr	4.06 Cr	3.61 Cr	2.65 Cr
Secured ST Loans repayable on Demands	4.3 Cr	4.06 Cr	3.61 Cr	2.65 Cr
Working Capital Loans- Sec	4.3 Cr	4.06 Cr	3.61 Cr	2.65 Cr
Short Term Provisions	68.02 Lk	74.73 Lk	88.59 Lk	1.05 Cr
Total Current Liabilities	97.45 Cr	92.74 Cr	82.57 Cr	79.42 Cr
Total Liabilities	555.85 Cr	579.14 Cr	601.08 Cr	626.82 Cr
Gross Block	616.32 Cr	612.5 Cr	603.74 Cr	617.51 Cr
Less: Accumulated Depreciation	354.63 Cr	371.57 Cr	387.78 Cr	398.98 Cr
Net Block	261.68 Cr	240.94 Cr	215.96 Cr	218.53 Cr
Capital Work in Progress	25.11 Cr	25.23 Cr	26.1 Cr	21.08 Cr
Non Current Investments	0	0	0	1.8 Lk
Long Term Investment	0	0	0	1.8 Lk
Unquoted	0	0	0	1.8 Lk
Long Term Loans & Advances	37.47 Cr	34.93 Cr	33.95 Cr	23.16 Cr
Other Non Current Assets	0	0	2.11 Cr	4.5 Cr
Total Non-Current Assets	324.26 Cr	301.1 Cr	278.12 Cr	267.3 Cr
Currents Investments	0	0	20.13 Cr	19.09 Cr
Quoted	0	0	20.13 Cr	19.09 Cr
Unquoted	0	0	0	1.8 Lk
Inventories	119.99 Cr	125.64 Cr	119.94 Cr	121.69 Cr
Raw Materials	66.04 Cr	75.4 Cr	77.63 Cr	75.03 Cr
Work-in Progress	36.66 Cr	34.04 Cr	24.82 Cr	20.14 Cr
Finished Goods	16.92 Cr	16.06 Cr	11.99 Cr	22.12 Cr
Sundry Debtors	32.04 Cr	38.6 Cr	76.66 Cr	80.5 Cr
Debtors more than Six months	0	1.73 Cr	3.05 Cr	2.15 Cr
Debtors Others	32.04 Cr	36.87 Cr	73.61 Cr	78.41 Cr
Cash and Bank	28.98 Cr	50.4 Cr	53.72 Cr	68.09 Cr
Cash in hand	9.27 Cr	7.56 Lk	16.23 Lk	15.03 Lk
Balances at Bank	19.71 Cr	50.32 Cr	53.55 Cr	67.94 Cr
Other Current Assets	5.7 Cr	5.01 Cr	1.78 Cr	1.32 Cr
Prepaid Expenses	50.18 Lk	49.76 Lk	67.44 Lk	63.4 Lk
Short Term Loans and Advances	44.88 Cr	58.39 Cr	50.73 Cr	68.83 Cr
Advances recoverable in cash or in kind	2.25 Cr	2.91 Cr	3.14 Cr	2.31 Cr
Advance income tax and TDS	28.72 Cr	28.51 Cr	31.84 Cr	36.93 Cr
Total Current Assets	231.6 Cr	278.04 Cr	322.96 Cr	359.52 Cr
Net Current Assets (Including Current Investments)	134.15 Cr	185.3 Cr	240.39 Cr	280.11 Cr
Total Assets	555.85 Cr	579.14 Cr	601.08 Cr	626.82 Cr
Contingent Liabilities	16.34 Lk	10.63 Cr	31.31 Cr	37.39 Cr
Total Debt	51.32 Cr	42.84 Cr	42.29 Cr	41.33 Cr
Book Value	313.18	329.5	0	364.74
Adjusted Book Value	313.18	329.5	344.38	364.74

STANDALONE BALANCE SHEET FOR VENUS REMEDIES LIMITED

YEAR	Mar 2021	Mar 2022	Mar 2023	Mar 2024
Share Capital	12.34 Cr	13.37 Cr	13.37 Cr	13.37 Cr
Equity - Authorised	20 Cr	20 Cr	20 Cr	20 Cr
Equity - Issued	12.34 Cr	13.37 Cr	13.37 Cr	13.37 Cr
Equity Paid Up	12.34 Cr	13.37 Cr	13.37 Cr	13.37 Cr
Face Value	10	10	10	10
Total Reserves	374.09 Cr	436.05 Cr	464.68 Cr	495.22 Cr
Securities Premium	75.6 Cr	88.33 Cr	88.33 Cr	88.33 Cr
Profit & Loss Account Balance	87.02 Cr	136.26 Cr	164.76 Cr	195.07 Cr
General Reserves	211.46 Cr	211.46 Cr	211.46 Cr	211.46 Cr
Reserve excluding Revaluation Reserve	374.09 Cr	436.05 Cr	464.68 Cr	495.22 Cr
Shareholder's Funds	400.18 Cr	449.41 Cr	478.05 Cr	508.59 Cr
Unsecured Loans	47.52 Cr	38.68 Cr	38.68 Cr	38.68 Cr
Foreign Currency Convertible Notes	38.68 Cr	38.68 Cr	38.68 Cr	38.68 Cr
Loans - Others	8.84 Cr	0	0	0
Deferred Tax Assets / Liabilities	3.63 Cr	-68.21 Lk	10.65 Cr	10.92 Cr
Deferred Tax Assets	28.03 Cr	26.99 Cr	10.34 Cr	6.82 Cr
Deferred Tax Liability	31.66 Cr	26.31 Cr	20.99 Cr	17.74 Cr
Other Long Term Liabilities	28.35 Lk	0	0	0
Long Term Provisions	7.38 Cr	7.95 Cr	8.85 Cr	10.26 Cr
Total Non-Current Liabilities	58.81 Cr	45.95 Cr	58.17 Cr	59.86 Cr
Trade Payables	68.36 Cr	49.63 Cr	48.51 Cr	42.7 Cr
Sundry Creditors	68.36 Cr	49.63 Cr	48.51 Cr	42.7 Cr
Other Current Liabilities	18.78 Cr	32.23 Cr	23.27 Cr	29.06 Cr
Advances received from customers	3.59 Cr	11.96 Cr	5.52 Cr	4.76 Cr
Short Term Provisions	68.02 Lk	74.73 Lk	88.59 Lk	1.05 Cr
Total Current Liabilities	87.82 Cr	82.61 Cr	72.67 Cr	72.81 Cr
Total Liabilities	546.81 Cr	577.98 Cr	608.89 Cr	641.26 Cr
Gross Block	581.73 Cr	578.19 Cr	568.5 Cr	581.97 Cr
Less: Accumulated Depreciation	337.53 Cr	353.52 Cr	368.82 Cr	379.21 Cr
Net Block	244.2 Cr	224.67 Cr	199.68 Cr	202.76 Cr
Capital Work in Progress	25.11 Cr	25.23 Cr	26.1 Cr	21.08 Cr
Non Current Investments	13.89 Lk	13.89 Lk	13.89 Lk	15.69 Lk
Long Term Investment	13.89 Lk	13.89 Lk	13.89 Lk	15.69 Lk
Unquoted	13.89 Lk	13.89 Lk	13.89 Lk	15.69 Lk
Long Term Loans & Advances	66.06 Cr	61.96 Cr	62.55 Cr	51.76 Cr
Other Non Current Assets	0	1.57 Cr	2.11 Cr	4.5 Cr
Total Non-Current Assets	335.51 Cr	313.57 Cr	290.58 Cr	280.26 Cr
Currents Investments	0	0	20.13 Cr	19.09 Cr
Quoted	0	0	20.13 Cr	19.09 Cr
Unquoted	13.89 Lk	13.89 Lk	13.89 Lk	15.69 Lk
Inventories	119.69 Cr	125.63 Cr	113.6 Cr	117.81 Cr
Raw Materials	66.04 Cr	75.4 Cr	77.63 Cr	75.03 Cr
Work-in Progress	36.66 Cr	34.04 Cr	24.82 Cr	20.14 Cr
Finished Goods	16.62 Cr	16.06 Cr	11.02 Cr	20.7 Cr
Sundry Debtors	16.44 Cr	30.41 Cr	84.92 Cr	89.54 Cr
Debtors more than Six months	0	65 Lk	3.02 Cr	2.77 Cr
Debtors Others	16.44 Cr	29.76 Cr	81.9 Cr	86.83 Cr
Cash and Bank	27.8 Cr	49.97 Cr	52.57 Cr	67.64 Cr
Cash in hand	8.09 Cr	7.4 Lk	15.94 Lk	14.53 Lk
Balances at Bank	19.71 Cr	49.89 Cr	52.41 Cr	67.5 Cr
Other Current Assets	5.7 Cr	5.01 Cr	2.63 Cr	1.32 Cr
Interest accrued on Investments	0	0	85.33 Lk	0
Prepaid Expenses	50.18 Lk	49.76 Lk	67.44 Lk	63.4 Lk
Short Term Loans and Advances	41.66 Cr	53.39 Cr	44.46 Cr	65.59 Cr
Advances recoverable in cash or in kind	2.25 Cr	2.91 Cr	3.14 Cr	2.31 Cr
Advance income tax and TDS	28.72 Cr	28.51 Cr	31.84 Cr	36.93 Cr
Total Current Assets	211.3 Cr	264.41 Cr	318.32 Cr	361 Cr
Net Current Assets (Including Current Investments)	123.48 Cr	181.8 Cr	245.65 Cr	288.18 Cr
Total Assets	546.81 Cr	577.98 Cr	608.89 Cr	641.26 Cr
Contingent Liabilities	16.34 Lk	10.63 Cr	31.31 Cr	37.39 Cr
Total Debt	47.52 Cr	38.68 Cr	38.68 Cr	38.68 Cr
Book Value	313.1	336.21	357.63	0
Adjusted Book Value	313.1	336.21	357.63	380.48

Consolidated Standalone

FINANCIAL RATIOS (CONSOLIDATED) FOR VENUS REMEDIES LIMITED

YEAR	Mar 2021	Mar 2022	Mar 2023	Mar 2024
Operational & Financial Ratios
Earnings Per Share (Rs)	50.04	30.47	19.87	21.31
CEPS(Rs)	78.63	55.55	44.04	41.1
Book NAV/Share(Rs)	313.18	329.5	344.38	364.74
Tax Rate(%)	-27.21	-11.85	29.96	36.18
Margin Ratios
Core EBITDA Margin(%)	9.81	10.38	10.84	9.91
EBIT Margin(%)	11.23	6.16	6.88	7.44
Pre Tax Margin(%)	8.86	6.08	6.83	7.42
PAT Margin (%)	11.27	6.8	4.78	4.74
Cash Profit Margin (%)	17.7	12.4	10.6	9.13
Performance Ratios
ROA(%)	10.3	7.18	4.5	4.64
ROE(%)	17.4	9.85	5.9	6.01
ROCE(%)	12.37	7.89	7.75	8.67
Asset Turnover(x)	0.91	1.05	0.94	0.98
Sales/Fixed Asset(x)	0.88	0.97	0.91	0.99
Working Capital/Sales(x)	4.09	3.23	2.31	2.15
Efficiency Ratios
Fixed Capital/Sales(x)	1.13	1.03	1.09	1.02
Receivable days	20.89	21.54	37.87	47.69
Inventory Days	86.94	74.88	80.68	73.32
Payable days	37.97	59.49	55.69	48.87
Valuation Parameters
PER(x)	5.49	8.82	8.15	15.31
PCE(x)	3.49	4.84	3.68	7.94
Price/Book(x)	0.88	0.82	0.47	0.89
EV/Net Sales(x)	0.66	0.59	0.37	0.68
EV/Core EBITDA(x)	4.92	5	2.91	5.75
EV/EBIT(x)	5.87	9.54	5.36	9.15
EV/CE(x)	0.65	0.61	0.34	0.77
M Cap / Sales	0.62	0.6	0.39	0.73
Growth Ratio
Net Sales Growth(%)	61.53	9.22	-7.44	8.27
Core EBITDA Growth(%)	59.14	-4.07	0.14	1.19
EBIT Growth(%)	1061.31	-40.09	3.62	17.58
PAT Growth(%)	717.7	-34.07	-34.77	7.25
EPS Growth(%)	717.7	-39.12	-34.77	7.25
Financial Stability Ratios
Total Debt/Equity(x)	0.13	0.1	0.09	0.08
Current Ratio(x)	2.38	3	3.91	4.53
Quick Ratio(x)	1.15	1.64	2.46	2.99
Interest Cover(x)	4.73	76.69	129.84	477.45
Total Debt/Mcap(x)	0.15	0.12	0.2	0.09

FINANCIAL RATIOS (STANDALONE) FOR VENUS REMEDIES LIMITED

YEAR	Mar 2021	Mar 2022	Mar 2023	Mar 2024
Operational & Financial Ratios
Earnings Per Share (Rs)	43.97	36.65	21.67	22.82
CEPS(Rs)	71.75	61.02	45.14	41.94
Book NAV/Share(Rs)	313.1	336.21	357.63	380.48
Tax Rate(%)	-32.18	-9.66	28.18	34.62
Margin Ratios
Core EBITDA Margin(%)	9.11	11.97	11.44	10.59
EBIT Margin(%)	10.45	7.77	7.5	8.11
Pre Tax Margin(%)	7.98	7.77	7.5	8.11
PAT Margin (%)	10.55	8.52	5.39	5.3
Cash Profit Margin (%)	17.21	14.18	11.22	9.75
Performance Ratios
ROA(%)	9.11	8.71	4.88	4.88
ROE(%)	15.1	11.72	6.25	6.18
ROCE(%)	10.8	9.55	8.03	8.77
Asset Turnover(x)	0.86	1.02	0.91	0.92
Sales/Fixed Asset(x)	0.88	0.99	0.94	1
Working Capital/Sales(x)	4.17	3.16	2.19	2
Efficiency Ratios
Fixed Capital/Sales(x)	1.14	1.01	1.07	1
Receivable days	16.39	14.87	39.15	55.35
Inventory Days	90.83	77.84	81.2	73.42
Payable days	37.76	57.28	53.2	47.26
Valuation Parameters
PER(x)	6.24	7.34	7.47	14.3
PCE(x)	3.83	4.41	3.59	7.78
Price/Book(x)	0.88	0.8	0.45	0.86
EV/Net Sales(x)	0.7	0.61	0.38	0.71
EV/Core EBITDA(x)	5.55	4.51	2.83	5.64
EV/EBIT(x)	6.67	7.79	5.02	8.73
EV/CE(x)	0.66	0.6	0.33	0.74
M Cap / Sales	0.66	0.62	0.4	0.76
Growth Ratio
Net Sales Growth(%)	60.7	11.77	-6.77	6.98
Core EBITDA Growth(%)	38.54	19.54	-7.19	0.71
EBIT Growth(%)	693	-16.95	-9.72	15.68
PAT Growth(%)	759.69	-9.74	-40.87	5.3
EPS Growth(%)	759.69	-16.66	-40.87	5.3
Financial Stability Ratios
Total Debt/Equity(x)	0.12	0.09	0.08	0.08
Current Ratio(x)	2.41	3.2	4.38	4.96
Quick Ratio(x)	1.04	1.68	2.82	3.34
Interest Cover(x)	4.23	0	0	0
Total Debt/Mcap(x)	0.14	0.11	0.18	0.09

SHARE HOLDING PATTERN FOR VENUS REMEDIES LIMITED

Date	Jun 2022	Sep 2022	Dec 2022	Mar 2023	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024
Promoters %	41.76	41.76	41.76	41.76	41.76	41.76	41.76	41.76	41.76	41.76
FII %	0.96	1.13	1.07	1.00	0.98	1.03	1.59	1.48	1.06	1.18
DII %	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Public %	57.28	57.11	57.17	57.24	57.26	57.21	56.65	56.76	57.18	57.06

PEER COMPARISON FOR VENUS REMEDIES LIMITED

No.	Name
1	AMBALAL SARABHAI ENTERPRISES LTD
2	Cipla Limited
3	Dr. Reddy's Laboratories Limited
4	Procter & Gamble Health Limited
5	J.K.PHARMACHEM LTD
6	Lupin Limited
7	Lyka Labs Limited
8	MESCO PHARMACEUTICALS LTD
9	Morepen Laboratories Limited
10	Piramal Enterprises Limited
11	Torrent Pharmaceuticals Limited
12	Abbott India Limited
13	GlaxoSmithKline Pharmaceuticals Limited
14	Sanofi India Limited
15	Pfizer Limited
16	Bliss GVS Pharma Limited
17	Alembic Limited
18	Unichem Laboratories Limited
19	AstraZeneca Pharma India Limited
20	GUJARAT THEMIS BIOSYN LTD
21	JB Chemicals & Pharmaceuticals Limited
22	TTK Healthcare Limited
23	Jagsonpal Pharmaceuticals Limited
24	Gufic Biosciences Limited
25	Sequent Scientific Limited
26	Albert David Limited
27	IOL Chemicals and Pharmaceuticals Limited
28	Wanbury Limited
29	Kopran Limited
30	Aarti Drugs Limited
31	Orchid Pharma Limited
32	Biofil Chemicals & Pharmaceuticals Limited
33	Marksans Pharma Limited
34	IPCA Laboratories Limited
35	Kilitch Drugs (India) Limited
36	Krebs Biochemicals and Industries Limited
37	Neuland Laboratories Limited
38	Ind-Swift Limited
39	Hester Biosciences Limited
40	Parenteral Drugs (India) Limited
41	Sun Pharmaceutical Industries Limited
42	Hikal Limited
43	Caplin Point Laboratories Limited
44	Aurobindo Pharma Limited
45	Natco Pharma Limited
46	Bal Pharma Limited
47	BDH INDUSTRIES LTD
48	Venus Remedies Limited
49	Jubilant Pharmova Limited
50	Themis Medicare Limited

CORPORATE ACTIONS FOR VENUS REMEDIES

Exchange Date	Purpose	Book Closure Dates
BSE 18-Oct-2024	Board Meeting - Quarterly Results	29-Oct-2024
BSE 19-Aug-2024	Book Closure - A.G.M.	17-Sep-2024 23-Sep-2024
BSE 19-Aug-2024	AGM - A.G.M.	23-Sep-2024 23-Sep-2024
BSE 01-Aug-2024	Board Meeting - Quarterly Results & A.G.M.	13-Aug-2024
BSE 18-Jul-2024	Board Meeting - (Cancelled) The Board Meeting to be held on 20/07/2024 Stands Cancelled.	20-Jul-2024
BSE 10-Jul-2024	Board Meeting - Inter alia, to consider and approve: 1. To consider the appointment of independent director. 2. To finalize the date of 35th Annual General Meeting of the company. 3. Any other business with permission of the Chair.	20-Jul-2024
BSE 21-May-2024	Board Meeting - Audited Results	30-May-2024
BSE 02-Feb-2024	Board Meeting - Quarterly Results	14-Feb-2024
BSE 30-Oct-2023	Board Meeting - Quarterly Results	09-Nov-2023
BSE 03-Aug-2023	Board Meeting - Quarterly Results	14-Aug-2023
BSE 14-Jul-2023	Book Closure - A.G.M.	18-Aug-2023 24-Aug-2023
BSE 14-Jul-2023	AGM - A.G.M.	24-Aug-2023 24-Aug-2023
BSE 05-Jul-2023	Board Meeting - VENUS REMEDIES LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 14/07/2023 ,inter alia, to consider and approve This is to inform you that the meeting of Board of Directors is scheduled to be held on 14th July 2023 inter alia: 1. To consider the appointment of Statutory Auditor of the Company. 2. To finalize the date of 34th Annual General Meeting of t...	14-Jul-2023
BSE 17-May-2023	Board Meeting - Audited Results	29-May-2023
BSE 19-Jan-2023	Board Meeting - Quarterly Results	30-Jan-2023
BSE 02-Nov-2022	Board Meeting - Quarterly Results	12-Nov-2022
BSE 25-Jul-2022	Board Meeting - Quarterly Results	30-Jul-2022
BSE 25-Jul-2022	Book Closure - A.G.M.	17-Aug-2022 23-Aug-2022
BSE 25-Jul-2022	AGM - A.G.M.	23-Aug-2022 23-Aug-2022
BSE 16-May-2022	Board Meeting - Audited Results	27-May-2022
BSE 20-Jan-2022	Board Meeting - Quarterly Results	31-Jan-2022
BSE 23-Dec-2021	Board Meeting - Inter alia, to consider the appointment of additional director Independent director.	30-Dec-2021
BSE 18-Oct-2021	Board Meeting - Quarterly Results	30-Oct-2021

CORPORATE ANNOUNCEMENTS FOR VENUS REMEDIES

Exchange Date	Category File	Description
BSE 30-Oct-2024	General Announcements FILE	Announcement under Regulation 30 (LODR)-Newspaper Publication Newspaper publication for UFR as on 30th Sep 2024.
BSE 29-Oct-2024	Outcome FILE	Financial Results As On 30.09.2024 Financial results as on 30.09.02024
BSE 29-Oct-2024	Outcome FILE	Board Meeting Outcome for Outcome Of Board Meeting Dated 29.10.24 Outcome of Board meeting dated 29.10.24
BSE 18-Oct-2024	Intimation FILE	Board Meeting Intimation for Boar Meeting Is Scheduled For 29Th October 2024. VENUS REMEDIES LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 29/10/2024 inter alia to consider and approve Boar meeting is scheduled for 29th October 2024 to inter alia consider and approve Unaudited financial results for the period ended on 30th September 2024.
BSE 08-Oct-2024	General Announcements FILE	Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018 Compliance certificate under regulation 74(5) of SEBI DP regulations.
BSE 05-Oct-2024	General Announcements FILE	Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate Loss of Shares_Stop Transfer compliance under regulation 39(3) of SEBI LODR.
BSE 30-Sep-2024	General Announcements FILE	Announcement under Regulation 30 (LODR)-Change in Management Completion of term of Dr. Suresh Kumar Chadha and Dr. Gilbert Wenzel from the position of Independent Directors of the Company.
BSE 24-Sep-2024	Outcome FILE	Shareholder Meeting / Postal Ballot-Scrutinizer''s Report Voting Results of 35th AGM.
BSE 24-Sep-2024	Intimation FILE	Closure of Trading Window Closure of Trading Window.
BSE 23-Sep-2024	General Announcements FILE	Announcement under Regulation 30 (LODR)-Change in Management Control Appointment of Independent Directors
BSE 23-Sep-2024	General Announcements FILE	Proceedings Of 35Th Annual General Meeting Held On 23Rd September 2024. Proceedings of 35th Annual General Meeting.
BSE 24-Aug-2024	General Announcements FILE	Announcement under Regulation 30 (LODR)-Newspaper Publication Newspaper publication for AGM Notice 2024.
BSE 21-Aug-2024	General Announcements FILE	Reg. 34 (1) Annual Report. Annual Report for the FY 2023-24
BSE 21-Aug-2024	General Announcements FILE	Reg. 34 (1) Annual Report. Annual Report for the FY 2023-24.
BSE 21-Aug-2024	Intimation FILE	Notice Of 35Th Annual General Meeting And Cut-Of-Date/ E-Voting Details of 35th Annual general Meeting as per the Copy of notice enclosed herewith.
BSE 21-Aug-2024	General Announcements FILE	Book Closure Notice Book Closure Notice.
BSE 16-Aug-2024	General Announcements FILE	Announcement under Regulation 30 (LODR)-Newspaper Publication News paper publication of AGM 2024 prior notice.
BSE 14-Aug-2024	General Announcements FILE	Announcement under Regulation 30 (LODR)-Newspaper Publication News paper publication of UFR for the quarter ended on 30th June 2024.
BSE 13-Aug-2024	General Announcements FILE	Announcement under Regulation 30 (LODR)-Change in Management Appointment of Independent Directors
BSE 13-Aug-2024	Outcome FILE	Financial Results For The Quarter Ended 30Th June 2024. Financial Results for the quarter ended 30th June 2024.
BSE 13-Aug-2024	Outcome FILE	Board Meeting Outcome for Outcome Of Board Meeting Dated 13.08.2024 outcome as per the pdf attached.
BSE 01-Aug-2024	Intimation FILE	Board Meeting Intimation for Notice Of Board Meeting To Be Held On 13Th August 2024. VENUS REMEDIES LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 13/08/2024 inter alia to consider and approve 1. To consider and approve Unaudited Standalone and Consolidated Financial Results for the period ended on 30th June 2024.2. To consider the appointment of independent director(s).3. To finalize the date of 35th Annual General Meeting of the company.4. Any other business with permission of the Chair.
BSE 17-Jul-2024	Intimation FILE	Cancellation of Board Meeting The Board Meeting to be held on 20/07/2024 Stands Cancelled.
BSE 12-Jul-2024	General Announcements FILE	Successful Resolution Of Income Tax Case And Refund Of Rs. 21.27 Crores Received By Venus Remedies Limited Venus Remedies is pleased to announce a significant milestone that Company has successfully won a longstanding case in the Honble Income tax Appellate Tribunal for the Assessment years 2009-10 2010-11 and 2011-12 against the Income Tax department. This favorable outcome has resulted in a refund of Rs.21.27 cr. from the Income Tax Department in compliance with the order of the Honble Income Tax Appellate Tribunal.
BSE 10-Jul-2024	Intimation FILE	Board Meeting Intimation for This Is To Inform You That The Meeting Of Board Of Directors Is Scheduled To Be Held On 20Th July 2024. VENUS REMEDIES LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 20/07/2024 inter alia to consider and approve This is to inform you that the meeting of Board of Directors is scheduled to be held on 20th July 2024 inter alia:1. To consider the appointment of independent director.2. To finalize the date of 35th Annual General Meeting of the company.3. Any other business with permission of the Chair.
BSE 08-Jul-2024	General Announcements FILE	Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018 Compliance under regulation 74(5) of SEBI DP regulations.
BSE 06-Jul-2024	General Announcements FILE	Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate Intimation for Stop transfer of shares.
BSE 29-Jun-2024	General Announcements FILE	Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate Compliance under reg 39(3) for stop transfer.
BSE 26-Jun-2024	Intimation FILE	Closure of Trading Window Closure of trading window
BSE 20-Jun-2024	General Announcements FILE	Venus Remedies Clinches WHO-Backed PAHO Tender Takes Its Global Fight Against Cancer To Next Level Venus Remedies Clinches WHO-backed PAHO Tender.

INSIDER TRADING FOR VENUS REMEDIES

Exchange Dates	Activity	Qty & Price (%)	Person / Organisation
BSE 30-May-2022 31-May-2022	Buy Market	126,946 @ 0.00 (0.95 %)	PAWAN CHAUDHARY
BSE 31-May-2021 31-May-2021	Buy Allotment	425,000 @ 0.00 (2.47 %)	MANU CHAUDHARY
BSE 31-May-2021 31-May-2021	Buy Allotment	600,000 @ 0.00 (3.87 %)	PAWAN CHAUDHARY

BULK BLOCK DEALS FOR VENUS REMEDIES LIMITED

Exchange Dates	Activity	Qty & Price (%)	Person / Organisation
No Bulk Block details found

DIVIDEND BY VENUS REMEDIES LIMITED

No dividend details found

SPLIT / BONUS BY VENUS REMEDIES LIMITED

No Split / Bonus details found

Data feed Source : www.accordfintech.com, NSE DATA Feed & BSE Data Feed

Facebook

Twitter

To TOP

Venus Remedies Limited

Venus Remedies share price

CONSOLIDATED QUARTERLY RESULT FOR VENUS REMEDIES LIMITED

STANDALONE QUARTERLY RESULT FOR VENUS REMEDIES LIMITED

CONSOLIDATED ANNUAL RESULT FOR VENUS REMEDIES LIMITED

STANDALONE ANNUAL RESULT FOR VENUS REMEDIES LIMITED

CONSOLIDATED PROFIT / LOSS FOR VENUS REMEDIES LIMITED

STANDALONE PROFIT / LOSS FOR VENUS REMEDIES LIMITED

CONSOLIDATED CASH FLOW FOR VENUS REMEDIES LIMITED

STANDALONE CASH FLOW FOR VENUS REMEDIES LIMITED

CONSOLIDATED BALANCE SHEET FOR VENUS REMEDIES LIMITED

STANDALONE BALANCE SHEET FOR VENUS REMEDIES LIMITED

FINANCIAL RATIOS (CONSOLIDATED) FOR VENUS REMEDIES LIMITED

FINANCIAL RATIOS (STANDALONE) FOR VENUS REMEDIES LIMITED

SHARE HOLDING PATTERN FOR VENUS REMEDIES LIMITED

PEER COMPARISON FOR VENUS REMEDIES LIMITED

CORPORATE ACTIONS FOR VENUS REMEDIES

CORPORATE ANNOUNCEMENTS FOR VENUS REMEDIES

INSIDER TRADING FOR VENUS REMEDIES

BULK BLOCK DEALS FOR VENUS REMEDIES LIMITED

DIVIDEND BY VENUS REMEDIES LIMITED

SPLIT / BONUS BY VENUS REMEDIES LIMITED